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Abstract 
Pseudomonas aeruginosa is the most common nosocomial pathogen, notorious for its multidrug resistance and 
causes life threatening infections. Carbapenems were considered as the last resort of drugs for the treatment of 
multi drug resistant P. aeruginosa infections. The emergence of resistance to carbapenems limits its use for treatment. 
Unlike other organisms, in P. aeruginosa intrinsic/chromosomal mediated resistance mechanisms plays a major role for 
carbapenem resistance rather than the carbapenemases. Carbapenemase producing organisms becomes resistant 
to both imipenem and meropenem. However, in our clinical settings, we have observed rare carbapenem resistant 
phenotypes such as imipenem resistant but meropenem susceptible (IRMS) and meropenem resistant but imipenem 
susceptible (MRIS) phenotypes. Thus we have chosen these rare phenotypes to look for the respective resistance 
mechanisms by phenotypic and molecular methods. From this study we found that, IRMS is primarily due to the 
mutations across various regions in the loops of oprD gene and MRIS is due to the over expression of mexAB efflux 
pumps. This study results confirms that, this rare phenotypes are due to the intrinsic/chromosomal mediated mecha-
nisms, which occurred due to the antibiotic selection pressure. This study also provided data concerning alterations 
in outer membrane permeability which is often associated with the increased levels of antibiotic efflux. Consequently, 
this study provided the prevalence of the various resistance mechanisms that have deployed by the organism to resist 
antibiotics through different phenotypes.
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Pseudomonas aeruginosa is a nosocomial pathogen 
which can cause a wide range of infections in humans, 
especially in immunocompromised patients. P. aerugi-
nosa has intrinsic resistance against most of the antip-
seudomonal drugs. Carbapenems are considered to be 
the drug of choice for the treatment of infections due to 
multi drug resistant P. aeruginosa. However, due to the 
inappropriate drug use and improper dosage of carbap-
enem, development of drug resistance can occur in clini-
cal settings. Among the carbapenems, imipenem is the 
least preferable drug, due to the high dose therapy with 
MIC of 4  µg/ml, whereas doripenem have an edge over 
meropenem and imipenem [1]. Unlike carbapenemase 
mediated resistance in Enterobacteriaceae, intrinsic 
mediated resistance mechanisms play a significant role 
for carbapenem resistance in P. aeruginosa. Mechanisms 
associated with carbapenem resistance can be classified 
as plasmid mediated and chromosomal mediated. Plas-
mid mediated are the carbapenemase enzymes which can 
hydrolyze imipenem  and meropenem; but doripenem 
to a lesser extent [2]. On the other hand, chromosomal 
mediated mechanism are specific for each carbapenems, 
such as, loss of porin (oprD) contributing to imipenem 
resistance and the overexpression of efflux pumps con-
tributing to meropenem resistance [3]. This is due to the 
target specific uptake and pumping out of carbapenems 
because of the structural variations. Clinical isolates that 
express either of these mechanisms contributes to differ-
ent types of phenotypes such as type I (imipenem resist-
ant meropenem susceptible—IRMS), type II (meropenem 
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resistant imipenem susceptible—MRIS) and type III 
(imipenem resistant meropenem resistant—IRMR). To 
understand the resistance mechanisms present among 
the P. aeruginosa, we have chosen isolates that shows dis-
crepancy in the carbapenem susceptibility pattern. These 
isolates were tested for various resistance mechanisms 
that contribute for such rare phenotype.
Generally, in our experience, isolates that harbor any 
of the plasmid mediated carbapenemases gene gives rise 
to type III (IRMR) phenotype of P. aeruginosa. However, 
we observed, type I (IRMS) and type II (MRIS) clinical 
isolates of P. aeruginosa in our clinical settings. There 
is very little information available on these rare pheno-
types, this study was carried out to characterize their 
respective resistance mechanisms responsible for such 
rare phenotypes. Based on the carbapenem susceptibility 
patterns, a total of seven IRMS and three MRIS isolates 
that showed discrepancy in the carbapenem suscepti-
bility were chosen for the study. All these isolates were 
isolated from blood and sputum samples between July 
and December 2014 from patients admitted in Christian 
Medical College, Vellore. The test isolates were identified 
up to species level as a part of routine diagnostic cultural 
identification methods and antimicrobial susceptibility 
testing was done by Kirby Bauer disc diffusion method, 
minimum inhibitory concentration (MIC) was deter-
mined for imipenem, meropenem and doripenem by 
E-test method (BioMerieux) and interpreted according 
to CLSI guidelines [4]. In addition, all the ten isolates 
were subjected to classical CarbaNP test using BPER-
II lysis protocol [5], modified hodge test according to 
CLSI guidelines [CLSI M100-S21], broth micro dilution 
using PAβN as an efflux pump inhibitor (at 20 µg/ml) in 
combination with levofloxacin and multiplex PCR for 
the detection of blaIMP [6], blaVIM [7], blaNDM [8], blaKPC 
[9] and blaOxa-48 like [10] genes. Relative quantification 
of oprD transcripts and mexAB efflux pumps was done 
by RT-qPCR [11] for IRMS and MRIS isolates respec-
tively as per the described methods. In addition, OprD 
gene was sequenced for all the seven isolates of IRMS P. 
aeruginosa at Christian Medical College, Vellore. (ABI 
Prism 3100 Genetic Analyzer—Applied Biosystems) and 
also multi locus sequence typing (MLST) was done as 
described previously [12].
The MICs of imipenem, meropenem and doripenem 
were given in Table  1. CarbaNP and modified hodge 
test showed all the isolates were negative, indicating the 
absence of carbapenemases. Subsequently, multiplex 
PCR for the detection of blaIMP, blaVIM, blaNDM, blaKPC 
and blaOxa-48 like genes were also negative and the results 
are mentioned in Table 1. This strongly indicates that the 
resistance mechanisms responsible for type I and type II 
susceptibility pattern were not due to the plasmid medi-
ated carbapenemases. Furthermore, upon sequencing of 
oprD gene in IRMS isolates, many different mutations 
were observed across various loops in the oprD porin. 
Table 1 Phenotypic and molecular characterization results of IRMS and MRIS P. aeruginosa isolates
Genes tested: blaIMP,blaVIM, blaNDM, blaKPC, blaOXA-48 like genes. Relative quantification of oprD and mexAB expression was normalized with ATCC 27853 P. 
aeruginosa with a value of 1.0 and the fold difference was mentioned above


























Imipenem resistant meropenem susceptible P. aeruginosa (IRMS)
 PA3970 4 4 4 Negative Negative Negative L4, L6 2.31 – –
 PA5778 6 1.5 1 Negative Negative Negative L4, L6 0.81 – ST 1685





 PA6192 4 2 0.5 Negative Negative Negative L2, L7, L8, L9, 
L15
0.16 – ST 1993
 PA6362 4 1 1 Negative Negative Negative L4, L6 1.27 – ST 360







 PA6476 4 1 1 Negative Negative Negative L2, L7, L8,
L9, L15
0.39 – ST 617
Meropenem resistant imipenem susceptible P. aeruginosa (MRIS)
 PA4381 6 4 3 Negative Negative Negative Not done Not done 3.37 –
 PA5350 4 32 4 Negative Negative Negative Not done Not done 2.54 –
 PA26815 3 8 12 Negative Negative Negative Not done Not done 1.09 –
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Relative quantification of oprD transcripts revealed 
that, out of 7 IRMS isolates, porin down regulation was 
observed in 3 of the isolates, while the other 4 isolates 
had basal level expression. On the other hand, MRIS iso-
lates showed over expression of mexAB efflux pumps and 
the results are mentioned in Table 2.
Expression of mRNA transcripts of oprD gene and 
mexB gene was analyzed by relative quantification in 
real time qPCR and the expression of study isolates were 
normalized with ATCC 27853 P. aeruginosa gene expres-
sions which is assigned a value of 1. Among the seven 
IRMS phenotypes, PA5778, PA6192 and PA6476 showed 
down regulation of oprD which was  <1.0 (Table  1). In 
addition, mutations was observed in; L2, L7, L8 L9 and 
L15 for PA6192 and PA6476. In PA5778, mutations were 
observed in L4 and L6 with a mutation of V436D, which 
was not reported in the literature so far. Whereas for, 
PA3970 and PA6362, oprD expression was not down reg-
ulated. However, PA3970 and PA6362 had mutations in 
loop 4 and loop 6 regions of oprD, which had an impact 
on imipenem resistance in these two isolates. In PA4745 
and PA6475, quantification of oprD transcripts was failed 
due to the presence of mutations in the primer bind-
ing regions of oprD gene. While sequencing of PA4745 
oprD gene revealed that there was huge deletion of about 
612 nucleotides which affects the L2, L7, L8, L9 and 
L15 regions which is the cause for imipenem resistance. 
These mutations except V436D were reported in previ-
ous studies [13]. Whereas, sequencing of oprD gene in 
PA6475 could not be accomplished due to the mutations 
in the forward primer binding regions, thus the mutation 
was not able to be determined by sequencing. Overall, 
mutations in oprD gene play a significant role in contrib-
uting resistance to imipenem in these isolates. Moreover, 
multi locus sequence typing showed that, the isolates of 
IRMS were not of the same sequence types. The differ-
ent sequence types were ST1685, ST1993, ST360, ST1952 
and ST617. These sequence types of IRMS isolates were 
previously found in Canada, China, Australia, Senegal, 
Brazil and The Netherlands (pubmlst.org).
Among three MRIS isolates, phenotypic characteri-
zation of efflux pumps with carbenicillin with PAβN 
showed  >  fourfold difference for PA4381 and PA5350, 
which was also correlated well with the relative quantifica-
tion of mexAB pump which showed >1 for mexB expression 
in comparison to the control ATCC 27853 P. aeruginosa. 
This confirms that the meropenem resistance in type II 
(MRIS) phenotypes was due to the over expression of 
mexAB pump. While one isolate PA26815 showed < four-
fold difference in the PAβN combination testing, which was 
also correlated with the real time quantification where, the 
mexAB expression was similar to ATCC 27853 P. aerugi-
nosa. However, while the cause for meropenem resistance 
is not due to the mexAB pump, it could be due to any other 
resistance mechanism which needs to be studied further.
The emergence of aforementioned phenotypes occurs 
mainly due to the antibiotic selection pressures promoted 
by inappropriate dosage and duration of the carbapen-
ems. Importantly, it is advisable to perform antimicrobial 
susceptibility testing for each of the carbapenems namely 
imipenem, meropenem and doripenem, rather than test-
ing single agent and extrapolating results for the other 
carbapenems. Apart from individual testing, another 
difficulty is in interpreting the results. This is due to the 
Table 2 Mutations observed in oprD gene of IRMS P. aeruginosa isolates
a Newly observed mutation which was not reported so far
Micro No. Amino acid
changes
Nucleotide changes Impact on oprD loops
Deletions Positions
PA3970 T103S, K115T, F170L None None L4, L6




L2, L7, L8, L9, L15






























L2, L7, L8, L9, L15
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differences in the breakpoint cut off recommended by 
CLSI [4] and EUCAST [14]. Wherein 2  µg/ml is being 
susceptible by CLSI and 2  µg/ml being resistant by 
EUCAST for doripenem. Such dissimilarities complicate 
the interpretation and use of doripenem which remains 
as the drug of choice for treating infections due to these 
phenotypes. It is important to avoid selection pressures 
which contribute for the emergence and spread of these 
discrepant phenotypes in clinical settings.
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